Keith Stewart

Title: Innovations in Cancer Treatment by Inventor Keith Stewart

Introduction

Keith Stewart is a prominent inventor based in Scottsdale, AZ, known for his significant contributions to cancer treatment through innovative therapies. With a total of three patents to his name, Stewart has focused on developing targeted therapies that address specific cancer types, particularly those involving NRG1 fusion events.

Latest Patents

Stewart's latest patents revolve around targeted therapies for cancer. These patents provide various embodiments that offer compositions and methods for detecting cancers containing an NRG1 fusion event. The therapeutic agents he has developed are specifically targeted to the NRG1 fusion, which is crucial for effective treatment. Exemplary compositions for treating these cancers may include therapeutic agents that inhibit Epidermal Growth Factor Receptor and/or ERBB2. Some of the notable agents include cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In certain embodiments, the therapeutic agent may consist of a combination of trastuzumab and pertuzumab.

Career Highlights

Throughout his career, Keith Stewart has worked with esteemed organizations such as the Translational Genomics Research Institute and Novartis AG. His work in these institutions has allowed him to collaborate with leading experts in the field of cancer research and treatment.

Collaborations

Some of his notable coworkers include John Carpten and David Craig, who have contributed to the advancements in cancer therapies alongside Stewart.

Conclusion

Keith Stewart's innovative work in developing targeted therapies for cancer has the potential to significantly improve treatment outcomes for patients. His dedication to research and collaboration with other experts in the field underscores the importance of innovation in the fight against cancer.